469 related articles for article (PubMed ID: 24782985)
21. Perturbation-Based Modeling Unveils the Autophagic Modulation of Chemosensitivity and Immunogenicity in Breast Cancer Cells.
Quiros-Fernandez I; Figueroa-Protti L; Arias-Arias JL; Brenes-Cordero N; Siles F; Mora J; Mora-Rodríguez RA
Metabolites; 2021 Sep; 11(9):. PubMed ID: 34564453
[TBL] [Abstract][Full Text] [Related]
22. Determinants for Antitumor and Protumor Effects of Programmed Cell Death.
Workenhe ST; Inkol JM; Westerveld MJ; Verburg SG; Worfolk SM; Walsh SR; Kallio KLF
Cancer Immunol Res; 2024 Jan; 12(1):7-16. PubMed ID: 37902605
[TBL] [Abstract][Full Text] [Related]
23. Dying for a cause: The pathogenic manipulation of cell death and efferocytic pathways.
Cooper KN; Potempa J; Bagaitkar J
Mol Oral Microbiol; 2023 Oct; ():. PubMed ID: 37786286
[TBL] [Abstract][Full Text] [Related]
24. Poroptosis: A form of cell death depending on plasma membrane nanopores formation.
Li H; Wang Z; Fang X; Zeng W; Yang Y; Jin L; Wei X; Qin Y; Wang C; Liang W
iScience; 2022 Jun; 25(6):104481. PubMed ID: 35712073
[TBL] [Abstract][Full Text] [Related]
25. Targeting phagocytosis to enhance antitumor immunity: (Trends in Cancer, 9:8 p:650-665, 2023).
Huntoon K; Lee D; Dong S; Antony A; Kim BYS; Jiang W
Trends Cancer; 2024 Jun; 10(6):571. PubMed ID: 37839974
[No Abstract] [Full Text] [Related]
26. Going viral with cancer immunotherapy.
Lichty BD; Breitbach CJ; Stojdl DF; Bell JC
Nat Rev Cancer; 2014 Aug; 14(8):559-67. PubMed ID: 24990523
[TBL] [Abstract][Full Text] [Related]
27. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
28. Consensus guidelines for the detection of immunogenic cell death.
Kepp O; Senovilla L; Vitale I; Vacchelli E; Adjemian S; Agostinis P; Apetoh L; Aranda F; Barnaba V; Bloy N; Bracci L; Breckpot K; Brough D; Buqué A; Castro MG; Cirone M; Colombo MI; Cremer I; Demaria S; Dini L; Eliopoulos AG; Faggioni A; Formenti SC; Fučíková J; Gabriele L; Gaipl US; Galon J; Garg A; Ghiringhelli F; Giese NA; Guo ZS; Hemminki A; Herrmann M; Hodge JW; Holdenrieder S; Honeychurch J; Hu HM; Huang X; Illidge TM; Kono K; Korbelik M; Krysko DV; Loi S; Lowenstein PR; Lugli E; Ma Y; Madeo F; Manfredi AA; Martins I; Mavilio D; Menger L; Merendino N; Michaud M; Mignot G; Mossman KL; Multhoff G; Oehler R; Palombo F; Panaretakis T; Pol J; Proietti E; Ricci JE; Riganti C; Rovere-Querini P; Rubartelli A; Sistigu A; Smyth MJ; Sonnemann J; Spisek R; Stagg J; Sukkurwala AQ; Tartour E; Thorburn A; Thorne SH; Vandenabeele P; Velotti F; Workenhe ST; Yang H; Zong WX; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014 Oct; 3(9):e955691. PubMed ID: 25941621
[TBL] [Abstract][Full Text] [Related]
29. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses.
Garg AD; Agostinis P
Immunol Rev; 2017 Nov; 280(1):126-148. PubMed ID: 29027218
[TBL] [Abstract][Full Text] [Related]
30. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.
Pol J; Vacchelli E; Aranda F; Castoldi F; Eggermont A; Cremer I; Sautès-Fridman C; Fucikova J; Galon J; Spisek R; Tartour E; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2015 Apr; 4(4):e1008866. PubMed ID: 26137404
[TBL] [Abstract][Full Text] [Related]
31. Combinatorial strategies for the induction of immunogenic cell death.
Bezu L; Gomes-de-Silva LC; Dewitte H; Breckpot K; Fucikova J; Spisek R; Galluzzi L; Kepp O; Kroemer G
Front Immunol; 2015; 6():187. PubMed ID: 25964783
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic viruses as immunotherapy: progress and remaining challenges.
Aurelian L
Onco Targets Ther; 2016; 9():2627-37. PubMed ID: 27226725
[TBL] [Abstract][Full Text] [Related]
33. Trial Watch: Chemotherapy with immunogenic cell death inducers.
Vacchelli E; Aranda F; Eggermont A; Galon J; Sautès-Fridman C; Cremer I; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014 Jan; 3(1):e27878. PubMed ID: 24800173
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.
Guo ZS; Liu Z; Kowalsky S; Feist M; Kalinski P; Lu B; Storkus WJ; Bartlett DL
Front Immunol; 2017; 8():555. PubMed ID: 28555136
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint modulation: rational design of combination strategies.
Zamarin D; Postow MA
Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic viruses as anticancer vaccines.
Woller N; Gürlevik E; Ureche CI; Schumacher A; Kühnel F
Front Oncol; 2014; 4():188. PubMed ID: 25101244
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.
Nguyen A; Ho L; Wan Y
Front Oncol; 2014; 4():145. PubMed ID: 24967214
[TBL] [Abstract][Full Text] [Related]
38. Immunogenic Apoptotic Cell Death and Anticancer Immunity.
Vandenabeele P; Vandecasteele K; Bachert C; Krysko O; Krysko DV
Adv Exp Med Biol; 2016; 930():133-49. PubMed ID: 27558820
[TBL] [Abstract][Full Text] [Related]
39. Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines.
Vandenberk L; Belmans J; Van Woensel M; Riva M; Van Gool SW
Front Immunol; 2015; 6():663. PubMed ID: 26834740
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land.
Guo ZS; Bartlett DL
Cancer Gene Ther; 2014 Jul; 21(7):261-3. PubMed ID: 25034971
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
